Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution.

Odabashian M, Carlotti E, Araf S, Okosun J, Spada F, Gribben JG, Forconi F, Stevenson F, Calaminici M, Krysov S.

Blood. 2020 Jan 13. pii: blood.2019002279. doi: 10.1182/blood.2019002279. [Epub ahead of print]

PMID:
31932843
2.

Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.

Gribben JG.

Br J Haematol. 2019 Dec 19. doi: 10.1111/bjh.16345. [Epub ahead of print] Review.

PMID:
31858596
3.

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.

J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9.

PMID:
31498031
4.

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcription.

Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, Dolnik A, Blätte TJ, Landau DA, Saub J, Estenfelder S, Ibach S, Cymbalista F, Leblond V, Delmer A, Bahlo J, Robrecht S, Fischer K, Goede V, Bullinger L, Wu CJ, Mertens D, Ficz G, Gribben JG, Hallek M, Döhner H, Stilgenbauer S.

Haematologica. 2019 Aug 29. pii: haematol.2019.217307. doi: 10.3324/haematol.2019.217307. [Epub ahead of print]

5.

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG.

Haematologica. 2019 Aug 14. pii: haematol.2019.223743. doi: 10.3324/haematol.2019.223743. [Epub ahead of print]

6.

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A, Schuh A, Pettitt A, Gribben JG, Patten PEM, Devereux S, Bloor A, Fox CP, Forconi F, Munir T.

J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11.

PMID:
31295041
7.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ.

Nature. 2019 Jun;570(7762):474-479. doi: 10.1038/s41586-019-1252-x. Epub 2019 May 29.

8.

Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma.

Zhang T, Guan XW, Gribben JG, Liu FT, Jia L.

Cell Death Dis. 2019 Apr 15;10(5):330. doi: 10.1038/s41419-019-1563-8.

9.

Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J, Clear A, Iqbal S, Davies JK, Johnson P, Calaminici M, Montoto S, Auer R, Chelala C, Gribben JG, Graham TA, Fest T, Fitzgibbon J, Okosun J.

Leukemia. 2019 Jun;33(6):1540. doi: 10.1038/s41375-019-0425-9.

PMID:
30903015
10.

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators.

J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21.

PMID:
30897038
11.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ.

Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.

12.
13.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW.

Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30522969
14.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M, Martinez A, Gonzalez-Farre B, Dlouhy I, González-Barca E, Terol MJ, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda JM, Sancho JM, Ribera JM, Mate JL, Navarro JT.

Leuk Lymphoma. 2019 Apr;60(4):1087-1091. doi: 10.1080/10428194.2018.1512711. Epub 2018 Oct 15. No abstract available.

PMID:
30322315
15.

Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P.

Am J Hematol. 2018 Nov;93(11):1402-1410. doi: 10.1002/ajh.25259. Epub 2018 Oct 9.

16.

No longer too exhausted to run.

Gribben JG.

Blood. 2018 Aug 2;132(5):464-465. doi: 10.1182/blood-2018-06-851642. No abstract available.

17.

How and when I do allogeneic transplant in CLL.

Gribben JG.

Blood. 2018 Jul 5;132(1):31-39. doi: 10.1182/blood-2018-01-785998. Epub 2018 May 11. Review.

19.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH.

J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.

PMID:
29584548
20.

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J, Clear A, Iqbal S, Davies JK, Johnson P, Calaminici M, Montoto S, Auer R, Chelala C, Gribben JG, Graham TA, Fest T, Fitzgibbon J, Okosun J.

Leukemia. 2018 May;32(5):1261-1265. doi: 10.1038/s41375-018-0043-y. Epub 2018 Feb 8. No abstract available. Erratum in: Leukemia. 2019 Jun;33(6):1540.

21.

Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin.

Dürr C, Hanna BS, Schulz A, Lucas F, Zucknick M, Benner A, Clear A, Ohl S, Öztürk S, Zenz T, Stilgenbauer S, Li-Weber M, Krammer PH, Gribben JG, Lichter P, Seiffert M.

Haematologica. 2018 Apr;103(4):688-697. doi: 10.3324/haematol.2017.177808. Epub 2018 Jan 11.

22.

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.

Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, Moreno C, Stilgenbauer S.

Br J Haematol. 2018 Mar;180(5):666-679. doi: 10.1111/bjh.15080. Epub 2018 Jan 9. Review.

PMID:
29318593
23.

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors.

Saunderson EA, Stepper P, Gomm JJ, Hoa L, Morgan A, Allen MD, Jones JL, Gribben JG, Jurkowski TP, Ficz G.

Nat Commun. 2017 Nov 13;8(1):1450. doi: 10.1038/s41467-017-01078-2.

24.

Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.

Davies JK, Hassan S, Sarker SJ, Besley C, Oakervee H, Smith M, Taussig D, Gribben JG, Cavenagh JD.

Br J Haematol. 2018 Feb;180(3):346-355. doi: 10.1111/bjh.14980. Epub 2017 Oct 26.

PMID:
29076145
25.

Restoring leukemia cell function from the inside out.

Gribben JG.

Blood. 2017 Jun 15;129(24):3137-3138. doi: 10.1182/blood-2017-04-776344. No abstract available.

PMID:
28620100
26.

Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.

Edelmann J, Gribben JG.

J Oncol Pract. 2017 Jun;13(6):371-377. doi: 10.1200/JOP.2017.023291. Review.

PMID:
28605616
27.

The role of stem cell transplant for lymphoma in 2017.

Gribben JG.

Hematol Oncol. 2017 Jun;35 Suppl 1:25-29. doi: 10.1002/hon.2396. Review. No abstract available.

PMID:
28591422
28.

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.

Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K, Gribben JG, Friedberg JW, Seymour JF, Cavalli F, Zucca E.

Hematol Oncol. 2017 Dec;35(4):397-407. doi: 10.1002/hon.2411. Epub 2017 Apr 4. Review.

PMID:
28378425
29.

Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells.

Lucas FM, Gribben JG.

Methods Mol Biol. 2017;1584:533-544. doi: 10.1007/978-1-4939-6881-7_33.

PMID:
28255724
30.

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.

Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P.

Leukemia. 2017 Oct;31(10):2085-2093. doi: 10.1038/leu.2017.65. Epub 2017 Apr 20.

31.

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).

Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, Desjardins P, Blonski JZ, Mei J, Golany N, Zhang J, Gribben JG.

Leukemia. 2017 May;31(5):1240-1243. doi: 10.1038/leu.2017.47. Epub 2017 Jan 31. No abstract available.

32.

Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition.

Dermit M, Casado P, Rajeeve V, Wilkes EH, Foxler DE, Campbell H, Critchlow S, Sharp TV, Gribben JG, Unwin R, Cutillas PR.

Oncogene. 2017 May 11;36(19):2762-2774. doi: 10.1038/onc.2016.435. Epub 2016 Dec 19.

33.

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.

Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S.

Leukemia. 2017 Mar;31(3):734-738. doi: 10.1038/leu.2016.317. Epub 2016 Nov 2. No abstract available.

34.

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.

Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner-Fritsch E, Launonen A, Sehn LH.

Ann Hematol. 2017 Feb;96(2):253-259. doi: 10.1007/s00277-016-2878-5. Epub 2016 Nov 30.

35.

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ.

Blood. 2016 Dec 22;128(25):2931-2940. doi: 10.1182/blood-2016-04-712562. Epub 2016 Nov 4.

36.

RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.

Salzer E, Cagdas D, Hons M, Mace EM, Garncarz W, Petronczki ÖY, Platzer R, Pfajfer L, Bilic I, Ban SA, Willmann KL, Mukherjee M, Supper V, Hsu HT, Banerjee PP, Sinha P, McClanahan F, Zlabinger GJ, Pickl WF, Gribben JG, Stockinger H, Bennett KL, Huppa JB, Dupré L, Sanal Ö, Jäger U, Sixt M, Tezcan I, Orange JS, Boztug K.

Nat Immunol. 2016 Dec;17(12):1352-1360. doi: 10.1038/ni.3575. Epub 2016 Oct 24.

37.

Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.

Riches JC, Gribben JG.

Curr Cancer Drug Targets. 2016;16(8):689-700. Review.

PMID:
27055579
39.

Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 May 27;48(6):700. doi: 10.1038/ng0616-700b. No abstract available.

PMID:
27230687
40.

Obinutuzumab for the treatment of indolent lymphoma.

Edelmann J, Gribben JG.

Future Oncol. 2016 Aug;12(15):1769-81. doi: 10.2217/fon-2016-0084. Epub 2016 Apr 27. Review.

41.

TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.

Kotsiou E, Okosun J, Besley C, Iqbal S, Matthews J, Fitzgibbon J, Gribben JG, Davies JK.

Blood. 2016 Jul 7;128(1):72-81. doi: 10.1182/blood-2015-10-679191. Epub 2016 Apr 21.

42.

Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules.

Kotsiou E, Gribben JG, Davies JK.

Mol Ther. 2016 Jun;24(6):1126-1134. doi: 10.1038/mt.2016.64. Epub 2016 Apr 6.

43.

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S.

Blood Cancer J. 2016 Mar 11;6:e404. doi: 10.1038/bcj.2016.9.

44.

Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients.

Griessinger E, Anjos-Afonso F, Vargaftig J, Taussig DC, Lassailly F, Prebet T, Imbert V, Nebout M, Vey N, Chabannon C, Filby A, Bollet-Quivogne F, Gribben JG, Peyron JF, Bonnet D.

Cancer Res. 2016 Apr 15;76(8):2082-6. doi: 10.1158/0008-5472.CAN-15-2063. Epub 2016 Mar 9.

45.

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).

Freeman CL, Gribben JG.

Curr Hematol Malig Rep. 2016 Feb;11(1):29-36. doi: 10.1007/s11899-015-0295-9. Review.

46.

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.

Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A.

Leuk Lymphoma. 2016;57(6):1291-9. doi: 10.3109/10428194.2015.1128540. Epub 2016 Jan 14.

PMID:
26763349
47.

Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.

Walsh C, Bonner JJ, Johnson TN, Neuhoff S, Ghazaly EA, Gribben JG, Boddy AV, Veal GJ.

Br J Clin Pharmacol. 2016 May;81(5):989-98. doi: 10.1111/bcp.12878. Epub 2016 Feb 25.

48.

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 Feb;48(2):183-8. doi: 10.1038/ng.3473. Epub 2015 Dec 21. Erratum in: Nat Genet. 2016 May 27;48(6):700.

49.

Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.

Hanna BS, McClanahan F, Yazdanparast H, Zaborsky N, Kalter V, Rößner PM, Benner A, Dürr C, Egle A, Gribben JG, Lichter P, Seiffert M.

Leukemia. 2016 Mar;30(3):570-9. doi: 10.1038/leu.2015.305. Epub 2015 Nov 2.

PMID:
26522085
50.

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M, Salles G, Cartron G.

Blood. 2015 Dec 10;126(24):2646-9. doi: 10.1182/blood-2015-09-670802. Epub 2015 Oct 7. No abstract available.

Supplemental Content

Loading ...
Support Center